Wuhan YZY Biopharma Co., Ltd.
Research Wuhan YZY Biopharma Co., Ltd. (2496.HK) on Bullrun: market cap HKD 678.47M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2496.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 678.47M
- Financial periodFY2025
- RevenueCNY 66.86M
- Revenue growth-38.0%
- Net income-CNY 84.73M
- Free cash flow-CNY 22.46M
- Gross margin16.1%
Valuation Snapshot
latest market cap is HKD 678.47M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 66.86M | -CNY 84.73M | -CNY 22.46M | 16.1% | n/a | CNY 100.07M | CNY 127.76M | -CNY 53.03M |
| FY2024 | CNY 107.81M | -CNY 97.60M | -CNY 102.22M | 78.9% | -0.5 | CNY 126.28M | CNY 127.35M | CNY 30.54M |
| FY2023 | CNY 0 | -CNY 191.70M | -CNY 187.95M | n/a | -1.04 | CNY 196.68M | CNY 90.11M | CNY 127.65M |
| FY2022 | CNY 0 | -CNY 188.87M | -CNY 178.11M | n/a | -0.98 | CNY 153.52M | CNY 76.67M | CNY 155.88M |
| FY2021 | n/a | n/a | n/a | n/a | -0.77 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 678.47M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Wuhan YZY Biopharma Co., Ltd.
Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-associated complications, and age-related ophthalmologic diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumors; wAMD, DME, and other ocular neovascularization-related diseases; hemophilia; and inflammatory bowel diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Wuhan YZY Biopharma Co., Ltd.'s market cap?
Wuhan YZY Biopharma Co., Ltd.'s market capitalization is HKD 678.47M.
What does Wuhan YZY Biopharma Co., Ltd. do?
Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-associated complications, and age-related ophthalmologic diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumors; wAMD, DME, and other ocular neovascularization-related diseases; hemophilia; and inflammatory bowel diseases. The company was founded in 2010 and is headquartered in Wuhan, China.